FDA warned Portugal OTC drug maker Fancystage Unipessoal of repeated CGMP failures, untested ingredients, unvalidated processes and misbranded fluoride mouthwash.
What happened
FDA inspected the company's drug manufacturing plant in Porto, Portugal, from January 22 to 26, 2024, and found it did not test incoming ingredients, had no data validating its manufacturing processes or equipment, counted microbes with test kits labeled for cosmetics, and let employees print and discard batch records without quality unit approval. The company had already been placed on Import Alert 66-40 (a list that lets FDA detain a firm's shipments without inspection) on May 8, 2023, and had been cited for similar CGMP problems in a warning letter dated August 3, 2023. FDA called the company's February 16, 2024 response inadequate because it lacked supporting documentation or evidence of corrective actions.
What FDA found
The company did not run an identity test on each incoming lot of ingredients, and it relied on suppliers' certificates of analysis without showing those suppliers' results were reliable.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company provided no data showing its manufacturing processes were validated (proven to work consistently) or that its equipment, such as bottle and tube filling, was qualified.
21 CFR 211.100(a)The company could not show that a system it uses both as a product ingredient and for cleaning equipment was validated or routinely monitored to meet microbial limits.
21 CFR 211.100(a)It measured total microbial counts in its OTC drugs with test kits labeled for cosmetics, without proving the methods were validated or equivalent to USP methods, and it had not qualified its contract testing laboratories.
21 CFR 211.160(b)The quality unit did not control records: staff could print and throw away batch records without approval, and original data were transcribed and then discarded.
21 CFR 211.22The mouthwash label tells users to swish for 30 seconds, but the OTC monograph for anticaries rinses requires 1 minute, so the product is misbranded because its label lacks adequate directions for use.
FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1); OTC Monograph M021.50(d)(2)
What FDA wants
FDA tells the company to correct the violations promptly and reply in writing within 15 working days with what it has done and how it will prevent recurrence. FDA also recommends hiring a qualified CGMP consultant to do a six-system audit before the firm seeks to resume making drugs for the U.S. market, and notes the firm remains on Import Alert 66-40.
Who should pay attention
- brands that contract-manufacture OTC mouthwash or other drugs at this site
- US importers and distributors of THE HUMBLE CO. anticavity mouthwash
- quality teams that accept supplier certificates of analysis instead of testing incoming ingredients
This is a summary. Read the original letter on fda.gov.